Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDAAA Impact Analysis (Year 7): The Era of the “Breakthrough” REMS

This article was originally published in RPM Report

Executive Summary

FDA continues to use the formal Risk Evaluation & Mitigation Strategy authority very infrequently in the context of new drug approvals. There is one countervailing trend: the agency is imposing mandatory communication plans for some of the new oncology therapies – including two “Breakthroughs.”


Related Content

FDAAA Fading? REMS Use Continues To Decline As Drug Safety Law Matures
Carving REMS Out of Oncology? FDA, ASCO Plan Follow-Up Workshop


Related Companies